Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Is there a correlation between HER-2/neu status and grade of the primary breast cancer? (CROSBI ID 101858)

Prilog u časopisu | stručni rad

Vučić, Majda ; Leniček, Tanja ; Čupić, Hrvoje ; Tomas, Davor ; Krušlin, Božo ; Belicza, Mladen Is there a correlation between HER-2/neu status and grade of the primary breast cancer? // Acta clinica Croatica, 42 (2003), 2; 183-188-x

Podaci o odgovornosti

Vučić, Majda ; Leniček, Tanja ; Čupić, Hrvoje ; Tomas, Davor ; Krušlin, Božo ; Belicza, Mladen

engleski

Is there a correlation between HER-2/neu status and grade of the primary breast cancer?

HER-2/neu amplification is a marker of poor prognosis in breast cancer. Patients whose tumors show overexpression of HER-2/neu have shortened disease-free and overall survival. The aim of this study was to determinate immunohistochemistry HER-2/neu overexpression in 121 cases of primary breast cancer. In addition HER-2/neu status was correlated with hormone receptor status, grades and pTNM stage. The both groups of HER-2/neu negative and HER-2/neu positive patients were average ages of about 60 years. In all the HER-2/neu groups (negative, 1+, 2+ and 3+) estrogen and progesterone receptor were highly positive in a high percentage of cases. Also in both groups of HER-2/neu negative and HER-2/neu positive invasive ductal carcinoma the most common grades were 2, but in HER-2/neu 3+ group, there were also 30.0% of cases having grade 3. Our results show that there might be a correlation between HER-2/neu overexpression and higher grade of breast cancer. The two most common pTNM stages were T1N0MX and T2N1MX. HER-2/neu receptor is important therapeutic target and testing for HER-2/neu status is now recommended as a part of routine breast cancer diagnosis. The role of new biomarkers, such as HER2/neu and clinical value of its determination must be provided by prospective clinical studies.

breast cancer; HER-2/neu; prognostic value

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

42 (2)

2003.

183-188-x

objavljeno

0353-9466

1333-9451

Povezanost rada

Javno zdravstvo i zdravstvena zaštita

Indeksiranost